Oncology and Hematology
257-272 of 743
Ryan Quigley
Casey Cosgrove, MD
Giuseppe Curigliano, MD, PhD
Giuseppe Curigliano, MD, PhD
Hiraji Iwata, MD, PhD
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
1.00 program creditKomal Jhaveri, MD, FACP
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
